Roche Annual General Meeting 2019

F. Hoffmann-La Roche Ltd / Roche Annual General Meeting 2019 . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement.

• All proposals of the Board of Directors approved

Christoph Franz as Chairman of the Roche Board of Directors and all other Board members standing for re-election approved; Professor Dr Hans Clevers elected as a new member of the Board of Directors

32th consecutive dividend increase to CHF 8.70 per share approved

Basel, 05 March 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM). The 840 attending shareholders, representing 86.73% of the total of 160,000,000 shares, approved the Management Report, the Financial Statements and the Consolidated Financial Statements for 2018.

Christoph Franz was confirmed as Chairman of the Board of Directors with 99.89% of the votes.

"2018 was a very strong year for Roche. Almost 90% of our growth came from newly launched products, demonstrating that we are successfully rejuvenating our portfolio. I am confident that we are well positioned for the future by pursuing our strategy of systematic innovation," said Christoph Franz, Chairman of Roche's Board of Directors. "I am delighted that Professor Dr Hans Clevers has been elected as a new member of the Board of Directors. He will strengthen the Board of Directors with his many years of expertise and experience in medical research."

Shareholders also authorised the ratification of the Board of Directors' actions and approved an increase in the gross dividend for the past financial year to 8.70 Swiss francs (gross) per share and non-voting equity security. This is the 32th consecutive dividend increase.

Shareholders endorsed the total amount of bonuses paid to the Corporate Executive Committee for 2018 with 99.59% of the votes, as well as the bonus paid to the Chairman of the Board of Directors for 2018, which was approved by 99.45% of the votes. They also approved the maximum total amount of future remuneration of the Board of Directors, which was confirmed by 99.60% of the votes, and the maximum total amount of future remuneration for the Corporate Executive Committee until the 2020 ordinary Annual General Meeting by 99.59% of the votes.